STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

PHASE2CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

May 28, 2023

Study Completion Date

May 28, 2023

Conditions
Intracerebral Haemorrhage
Interventions
DRUG

Tranexamic Acid

Investigational product given within 2 hours of symptom onset

DRUG

Normal saline

Placebo given within 2 hours of symptom onset

Trial Locations (25)

100

National Taiwan University Hospital, Taipei

2050

Royal Prince Alfred Hospital, Camperdown

2170

Liverpool Hospital, Liverpool

2305

John Hunter Hospital, New Lambton Heights

3004

Alfred Hospital, Melbourne

3050

Mobile Stroke Unit, Parkville

3065

St Vincent's Hospital Melbourne, Fitzroy

3084

Austin Hospital, Heidelberg

3128

Box Hill Hospital, Box Hill

3168

Monash Medical Centre, Clayton

3220

University Hospital Geelong, Geelong

4102

Princess Alexandra Hospital, Woolloongabba

4215

Gold Coast University Hospital, Southport

4442

Palmerston North Hospital, Palmerston North

4575

Sunshine Coast University Hospital, Birtinya

5000

Royal Adelaide Hospital, Adelaide

6021

Wellington Hospital, Wellington

8140

CDHB Christchurch Hospital, Christchurch

40447

China Medical University Hospital, Taichung

Unknown

Royal Melbourne Hospital, Melbourne

Helsinki University Hospital, Helsinki

E-DA Hospital, Kaohsiung City

Bach Mai Hospital, Hanoi

Military 103 Hospital, Hanoi

Nguyen Tri Phuong Hospital, Ho Chi Minh City

Sponsors
All Listed Sponsors
collaborator

The Florey Institute of Neuroscience and Mental Health

OTHER

lead

Neuroscience Trials Australia

OTHER

NCT03385928 - STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units | Biotech Hunter | Biotech Hunter